Inobrodib

Phase 2Small molecule

CCellCentric Ltd.

Inobrodib is one of 3 small molecule programs targeting Multiple Myeloma, Refractory. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Myeloma, RefractoryRecruiting

Multiple Myeloma, RefractoryPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Multiple Myeloma, Refractory

#DrugCompanyPhaseTrials

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 2

Decadron

AAspen Global Incorporated

Phase 2

1 3

Inobrodib

CCellCentric Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Multiple Myeloma, Refractory

NCT07096778

Clinical

Trials by Indication[1]

Multiple Myeloma, Refractory1 trial

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·CCellCentric Ltd.·Phase 2·NCT07096778·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inobrodib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inobrodib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inobrodib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CellCentric Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCellCentric Ltd.

Inobrodib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Multiple Myeloma, Refractory1 trial

References

Drug Info

Quick Facts

Related News